Hemispherx Biopharma, Inc.

Company Listings from SPi: Hemispherx Biopharma, Inc.

You are here: Home >> SPi Company Listings >> Hemispherx Biopharma, Inc.

 

Hemispherx Biopharma, Inc.

Website:
http://

Search for other references to "hemispherx" on SPi News

Latest Hemispherx Biopharma, Inc. News

Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma OCALA, Fla., Oct. 10, 2018 (GLOBE NEWSWIRE) -- announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in combinati...... 13:30 GMT Wednesday 10th October 2018

Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe ORLANDO, Fla., Sept. 18, 2018 (GLOBE NEWSWIRE) -- announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen&...... 13:30 GMT Tuesday 18th September 2018

Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order ORLANDO, Fla., Aug. 28, 2018 (GLOBE NEWSWIRE) -- (NYSE American: HEB) announced today that the new Ampligen batch manufactured earlier this year is now released  for patients' u...... 13:30 GMT Tuesday 28th August 2018

Hemispherx to Present at the 20th Annual Rodman & Renshaw Global Investment Conference ORLANDO, Fla., Aug. 24, 2018 (GLOBE NEWSWIRE) -- (NYSE American: HEB) an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, an...... 13:30 GMT Friday 24th August 2018

Hemispherx Reports Six Months Ended June 30, 2018 Financial Results and Provides Business Update OCALA, Fla., Aug. 15, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, has...... 13:38 GMT Wednesday 15th August 2018

Hemispherx Updates Stockholders, Highlighting Ampligen’s Role in Enhancing Immunotherapeutic Therapies OCALA, Fla., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medic...... 13:30 GMT Monday 13th August 2018

Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine ORLANDO, Fla., July 09, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB) announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen® in...... 13:30 GMT Monday 9th July 2018

Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies ORLANDO, Fla., July 03, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB), an immuno-pharma R&D company focused on unmet medical needs in immunology, is pleased to enthusiastically su...... 13:30 GMT Tuesday 3rd July 2018

Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina ORLANDO, Fla., June 27, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the immediate expansion of its Treatment Protocol/Expanded Access Pr...... 13:30 GMT Wednesday 27th June 2018

Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot ORLANDO, Fla., June 15, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the successful completion of the first phase of its Ampligen product...... 15:19 GMT Friday 15th June 2018

Buy Hemispherx Biopharma, Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us